Jemal Hussien Ahmed
Overview
Explore the profile of Jemal Hussien Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chala A, Kitabi E, Ahmed J, Tadesse B, Chaka T, Makonnen E, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Feb;
12(6):783-794.
PMID: 36840416
Despite the potential for efavirenz (EFV) to be an effective alternative antiretroviral agent, its sources of wide inter- and intra-individual pharmacokinetic (PK) variability are not well-characterized in children. We investigated...
2.
Abza G, Ahmed J, Yesufe A, Seife E, Erkie M, Spriet I, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612189
(1) Background: Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, killing over 700,000 people each year. Despite the rising incidence and mortality rates of HCC in Ethiopia, only...
3.
Ahmed J, Makonnen E, Bisaso R, Mukonzo J, Fotoohi A, Aseffa A, et al.
Front Pharmacol
. 2020 May;
11:406.
PMID: 32390827
Cyclophosphamide (CPA) containing chemotherapy regimen is the standard of care for breast cancer treatment in sub-Saharan Africa. Wide inter-individual variations in pharmacokinetics (PK) of cyclophosphamide (CPA) influence the efficacy and...
4.
Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
Ahmed J, Makonnen E, Fotoohi A, Aseffa A, Howe R, Aklillu E
Cancers (Basel)
. 2019 Sep;
11(9).
PMID: 31547390
Tamoxifen displays wide inter-individual variability (IIV) in its pharmacokinetics and treatment outcome. Data on tamoxifen pharmacokinetics and pharmacogenetics from black African breast cancer patient populations is lacking. We investigated the...
5.
Ahmed J, Makonnen E, Yimer G, Seifu D, Bekele A, Assefa M, et al.
Front Pharmacol
. 2019 May;
10:481.
PMID: 31139078
Chemotherapy-induced hematologic toxicity is the primary reasons of dose reductions and/or delays, low relative dose intensity (RDI), and predicts anticancer response. We investigated the incidence and predictors of chemotherapy-induced hematologic...
6.
Ahmed J, Makonnen E, Fotoohi A, Yimer G, Seifu D, Assefa M, et al.
Nutrients
. 2019 Feb;
11(2).
PMID: 30699973
Emerging evidence associates vitamin D deficiency and vitamin D receptor () genetic variations with risk for breast cancer. This study investigated the prevalence of vitamin D deficiency and its association...